Full Text Journal Articles by
Author Jonathan S Berek

Advertisement

Find full text journal articles






FIGO staging for carcinoma of the vulva: 2021 revision.

Alexander B Olawaiye, Joseph Cotler, Mauricio A Cuello, Neerja Bhatla, Aikou Okamoto, Sarikapan Wilailak, Chittaranjan N Purandare, Gerhard Lindeque, Jonathan S Berek, Sean Kehoe,

To revise the FIGO staging for carcinoma of the vulva using a new approach that involves analyses of prospectively collected data. The FIGO Committee for Gynecologic Oncology reviewed the recent literature to gain an insight into the impact of the 2009 vulvar cancer staging revision. The Committee resolved to revise ... Read more >>

Int J Gynaecol Obstet (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics)
[2021, 155(1):43-47]

Cited: 0 times

View full text PDF listing >>



Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer.

Allison W Kurian, Paul Abrahamse, Irina Bondarenko, Ann S Hamilton, Dennis Deapen, Scarlett L Gomez, Monica Morrow, Jonathan S Berek, Timothy P Hofer, Steven J Katz, Kevin C Ward,

<h4>Background</h4>Breast cancer and ovarian cancer patients increasingly undergo germline genetic testing. However, little is known about cancer-specific mortality among carriers of a pathogenic variant (PV) in BRCA1/2 or other genes in a population-based setting.<h4>Methods</h4>Georgia and California Surveillance Epidemiology and End Results (SEER) registry records were linked to clinical genetic testing ... Read more >>

J Natl Cancer Inst (Journal of the National Cancer Institute)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Greater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivors.

Catherine Benedict, Sophie Fisher, Lidia Schapira, Sabrina Chao, Sarah Sackeyfio, Tara Sullivan, Erqi Pollom, Jonathan S Berek, Allison W Kurian, Oxana Palesh,

<h4>Background</h4>Financial toxicity includes distress and burden from cancer-related costs. Women are more likely to experience worse cancer-related financial outcomes than men. This study evaluated breast and gynecologic cancer patients' subjective experiences of financial toxicity and associations with distress and quality of life (QOL).<h4>Methods</h4>A cross-sectional survey study included measures of financial ... Read more >>

Psychooncology (Psycho-oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.

Allison W Kurian, Kevin C Ward, Paul Abrahamse, Irina Bondarenko, Ann S Hamilton, Dennis Deapen, Monica Morrow, Jonathan S Berek, Timothy P Hofer, Steven J Katz,

<h4>Purpose</h4>Genetic testing is important for breast and ovarian cancer risk reduction and treatment, yet little is known about its evolving use.<h4>Methods</h4>SEER records of women of age ≥ 20 years diagnosed with breast or ovarian cancer from 2013 to 2017 in California or Georgia were linked to the results of clinical ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2021, 39(15):1631-1640]

Cited: 1 time

View full text PDF listing >>



Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.

Jean-Emmanuel Kurtz, Val Gebski, Vladyslav Sukhin, Mark Carey, Iwa Kong, Rosalind M Glasspool, Jonathan S Berek, Mariana de Paiva Batista, Marcia Hall, Jae-Weon Kim, Effi Yeoshoua, Noriko Fujiwara, Byung-Ho Nam, Sandra Polleis, Jung-Yun Lee, Aleksandra Strojna, Laura Farrelly, Richard Schwameis, Roldano Fossati, Anne-Sophie Darlington, Chyong-Huey Lai, Alexi A Wright, Orgad Rosenblat, Phillip Harter, Patricia Roxburgh, Rahul Roy Chowdhury, Ting-Chang Chang, Xavier Paoletti, Michael Friedlander, ,

<h4>Background</h4>Quality of life and patient reported outcome measures (PROMs) are important secondary endpoints and incorporated in most contemporary clinical trials. There have been deficiencies in their assessment and reporting in ovarian cancer clinical trials, particularly in trials of maintenance treatment where they are of particular importance. The Gynecologic Cancer InterGroup ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, 161(2):502-507]

Cited: 0 times

View full text PDF listing >>



Cell-based immunotherapy in gynecologic malignancies.

Kalika Kamat, Venkatesh Krishnan, Jonathan S Berek, Oliver Dorigo,

<h4>Purpose of review</h4>To provide an update on cell-based immunotherapies in solid tumors particularly in gynecological cancers.<h4>Recent findings</h4>Recent clinical trial results demonstrate safety and tolerability of different cell therapies in gynecological cancers. Novel approaches, such as harnessing the cells of the innate immune system are also under investigation in a phase ... Read more >>

Curr Opin Obstet Gynecol (Current opinion in obstetrics & gynecology)
[2021, 33(1):13-18]

Cited: 0 times

View full text PDF listing >>



Predictors of Survival Outcomes After Primary Treatment of Epithelial Ovarian Cancer in Lagos, Nigeria.

Kehinde Sharafadeen Okunade, Adebola A Adejimi, Ephraim O Ohazurike, Omolola Salako, Benedetto Osunwusi, Muisi A Adenekan, Aloy O Ugwu, Adaiah Soibi-Harry, Olayemi Dawodu, Adeyemi A Okunowo, Rose I Anorlu, Jonathan S Berek,

<h4>Purpose</h4>This study was designed to investigate the clinicopathologic predictors of progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (EOC) following primary treatment in Lagos, Nigeria.<h4>Materials and methods</h4>Using data from a retrospective cohort of 126 patients who received treatment for EOC between 2010 and 2018, we ... Read more >>

JCO Glob Oncol (JCO global oncology)
[2021, 7:89-98]

Cited: 1 time

View full text PDF listing >>



Patterns of social media use and associations with psychosocial outcomes among breast and gynecologic cancer survivors.

Leah T Tolby, Elisa N Hofmeister, Sophie Fisher, Sabrina Chao, Catherine Benedict, Allison W Kurian, Jonathan S Berek, Lidia Schapira, Oxana G Palesh,

<h4>Purpose</h4>We sought to characterize the use of social media (SM) among breast and gynecologic cancer survivors, as well as associations between patterns of SM use and psychosocial outcomes.<h4>Methods</h4>Two hundred seventy-three breast and gynecologic cancer survivors recruited at the Stanford Women's Cancer Center completed the study. Participants completed questionnaires to measure ... Read more >>

J Cancer Surviv (Journal of cancer survivorship : research and practice)
[2021, 15(5):677-684]

Cited: 0 times

View full text PDF listing >>



Development of Therapeutic Vaccines for Ovarian Cancer.

Stephanie Chow, Jonathan S Berek, Oliver Dorigo,

Ovarian cancer remains the deadliest of all gynecologic malignancies. Our expanding knowledge of ovarian cancer immunology has allowed the development of therapies that generate systemic anti-tumor immune responses. Current immunotherapeutic strategies include immune checkpoint blockade, cellular therapies, and cancer vaccines. Vaccine-based therapies are designed to induce both adaptive and innate ... Read more >>

Vaccines (Basel) (Vaccines)
[2020, 8(4):]

Cited: 2 times

View full text PDF listing >>



Impact of mobile technologies on cervical cancer screening practices in Lagos, Nigeria (mHealth-Cervix): Protocol for a randomised controlled trial.

Kehinde S Okunade, Omolola Salako, Adebola A Adejimi, Oluwatosin J Akinsola, Omolara Fatiregun, Muisi A Adenekan, Olusanjo E Moses, Bassey Ebenso, Matthew J Allsop, Rose I Anorlu, Jonathan S Berek,

<b>Background:</b> Incidence and mortality from cervical cancer have remained high due to many obstacles facing the implementation of organized screening programs in resource-constrained countries such as Nigeria. The application of mobile technologies (mHealth) to health services delivery has the potential to reduce inequalities, empower patients to control their health, and ... Read more >>

F1000Res (F1000Research)
[2020, 9:322]

Cited: 0 times

View full text PDF listing >>



NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.

Deborah K Armstrong, Ronald D Alvarez, Jamie N Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S Berek, Lee-May Chen, Mihaela Cristea, Marie DeRosa, Adam C ElNaggar, David M Gershenson, Heidi J Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A Leath, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M O'Malley, Richard T Penson, Sanja Percac-Lima, Elena Ratner, Steven W Remmenga, Paul Sabbatini, Theresa L Werner, Emese Zsiros, Jennifer L Burns, Anita M Engh,

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in ... Read more >>

J Natl Compr Canc Netw (Journal of the National Comprehensive Cancer Network : JNCCN)
[2019, 17(8):896-909]

Cited: 49 times

View full text PDF listing >>



Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.

Josep M Del Campo, Ursula A Matulonis, Susanne Malander, Diane Provencher, Sven Mahner, Philippe Follana, Justin Waters, Jonathan S Berek, Kathrine Woie, Amit M Oza, Ulrich Canzler, Marta Gil-Martin, Anne Lesoin, Bradley J Monk, Bente Lund, Lucy Gilbert, Robert M Wenham, Benedict Benigno, Sujata Arora, Sebastien J Hazard, Mansoor R Mirza,

<h4>Purpose</h4>In the ENGOT-OV16/NOVA trial (ClinicalTrials.gov identifier: NCT01847274), maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, prolonged progression-free survival in patients with platinum-sensitive, recurrent ovarian cancer who had a response to their last platinum-based chemotherapy. The objective of the study was to assess the clinical benefit and patient-reported outcomes in patients ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2019, 37(32):2968-2973]

Cited: 20 times

View full text PDF listing >>



Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, David Scott Miller, Noelle Cloven, Gini F Fleming, Andrea E Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M Oza, Mihaela Cristea, Jonathan S Berek, John K Chan, Bobbie J Rimel, Daniela E Matei, Yong Li, Kaiming Sun, Katarina Luptakova, Ursula A Matulonis, Bradley J Monk,

<h4>Background</h4>Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%, and median overall survival after third-line therapy of 5-9 months. In this study (QUADRA), we investigated the activity of niraparib monotherapy as the fourth or later line ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2019, 20(5):636-648]

Cited: 71 times

View full text PDF listing >>



Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri.

Jonathan S Berek, Koji Matsuo, Brendan H Grubbs, David K Gaffney, Susanna I Lee, Aoife Kilcoyne, Gi Jeong Cheon, Chong Woo Yoo, Lu Li, Yifeng Shao, Tianhui Chen, Miseon Kim, Mikio Mikami,

J Gynecol Oncol (Journal of gynecologic oncology)
[2019, 30(2):e40]

Cited: 6 times

View full text PDF listing >>



Revised FIGO staging for carcinoma of the cervix uteri.

Neerja Bhatla, Jonathan S Berek, Mauricio Cuello Fredes, Lynette A Denny, Seija Grenman, Kanishka Karunaratne, Sean T Kehoe, Ikuo Konishi, Alexander B Olawaiye, Jaime Prat, Rengaswamy Sankaranarayanan, James Brierley, David Mutch, Denis Querleu, David Cibula, Michael Quinn, Hennie Botha, Lax Sigurd, Laurel Rice, Hee-Sug Ryu, Hextan Ngan, Johanna Mäenpää, Andri Andrijono, Gatot Purwoto, Amita Maheshwari, Uttam D Bafna, Marie Plante, Jayashree Natarajan,

<h4>Objective</h4>To revise FIGO staging of carcinoma of the cervix uteri, allowing incorporation of imaging and/or pathological findings, and clinical assessment of tumor size and disease extent.<h4>Methods</h4>Review of literature and consensus view of the FIGO Gynecologic Oncology Committee and related societies and organizations.<h4>Results</h4>In stage I, revision of the definition of microinvasion ... Read more >>

Int J Gynaecol Obstet (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics)
[2019, 145(1):129-135]

Cited: 88 times

View full text PDF listing >>



Cancer of the ovary, fallopian tube, and peritoneum.

Jonathan S Berek, Sean T Kehoe, Lalit Kumar, Michael Friedlander,

The Gynecologic Oncology Committee of FIGO in 2014 revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or ... Read more >>

Int J Gynaecol Obstet (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics)
[2018, 143 Suppl 2:59-78]

Cited: 32 times

View full text PDF listing >>



Occult Gynecologic Cancer in Women Undergoing Hysterectomy or Myomectomy for Benign Indications.

Eva Chalas, Daniel Clarke-Pearson, Jonathan S Berek,

Obstet Gynecol (Obstetrics and gynecology)
[2018, 132(2):519]

Cited: 1 time

View full text PDF listing >>



Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.

Amit M Oza, Ursula A Matulonis, Susanne Malander, Stacie Hudgens, Jalid Sehouli, Josep M Del Campo, Dominique Berton-Rigaud, Susana Banerjee, Giovanni Scambia, Jonathan S Berek, Bente Lund, Anna V Tinker, Felix Hilpert, Isabel Palacio Vázquez, Véronique D'Hondt, Benedict Benigno, Diane Provencher, Joseph Buscema, Shefali Agarwal, Mansoor R Mirza,

<h4>Background</h4>Quality of life (QOL) has become an important complementary endpoint in cancer clinical studies alongside more traditional assessments (eg, tumour response, progression-free survival, overall survival). Niraparib maintenance treatment has been shown to significantly improve progression-free survival in patients with recurrent ovarian cancer. We aimed to assess whether the benefits of ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2018, 19(8):1117-1125]

Cited: 26 times

View full text PDF listing >>



30 years of Current Opinion in Obstetrics and Gynecology: looking back and looking forward.

Jonathan S Berek,

Curr Opin Obstet Gynecol (Current opinion in obstetrics & gynecology)
[2018, 30(2):99]

Cited: 0 times

View full text PDF listing >>



Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation".

William H Parker, Jonathan S Berek, Elizabeth A Pritts, David Olive, Eva Chalas, Daniel Clarke-Pearson,

J Minim Invasive Gynecol (Journal of minimally invasive gynecology)
[2018, 25(6):1113]

Cited: 0 times

View full text PDF listing >>



Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.

Madeleine T King, Martin R Stockler, Rachel L O'Connell, Luke Buizen, Florence Joly, Anne Lanceley, Felix Hilpert, Aikou Okamoto, Eriko Aotani, Jane Bryce, Paul Donnellan, Amit Oza, Elisabeth Avall-Lundqvist, Jonathan S Berek, Jalid Sehouli, Amanda Feeney, Dominique Berton-Rigaud, Daniel S J Costa, Michael L Friedlander, ,

<h4>Purpose</h4>Gynecologic Cancer Intergroup Symptom Benefit Study (GCIG-SBS) Stage 2 aimed to review, revise, and validate a patient-reported outcome measure (PROM), the Measure of Ovarian Symptoms and Treatment concerns (MOST), developed in GCIG-SBS Stage 1 (MOSTv1, 35 items), and document recurrent ovarian cancer (ROC) symptom burden and benefit.<h4>Methods</h4>GCIG-SBS Stage 2 recruited ... Read more >>

Qual Life Res (Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation)
[2018, 27(1):59-74]

Cited: 8 times

View full text PDF listing >>



Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry.

Veronica D Gonzalez, Nikolay Samusik, Tiffany J Chen, Erica S Savig, Nima Aghaeepour, David A Quigley, Ying-Wen Huang, Valeria Giangarrà, Alexander D Borowsky, Neil E Hubbard, Shih-Yu Chen, Guojun Han, Alan Ashworth, Thomas J Kipps, Jonathan S Berek, Garry P Nolan, Wendy J Fantl,

We have performed an in-depth single-cell phenotypic characterization of high-grade serous ovarian cancer (HGSOC) by multiparametric mass cytometry (CyTOF). Using a CyTOF antibody panel to interrogate features of HGSOC biology, combined with unsupervised computational analysis, we identified noteworthy cell types co-occurring across the tumors. In addition to a dominant cell ... Read more >>

Cell Rep (Cell reports)
[2018, 22(7):1875-1888]

Cited: 31 times

View full text PDF listing >>



Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation".

William H Parker, Jonathan S Berek, Elizabeth A Pritts, David Olive, Eva Chalas, Dan Clarke-Pearson,

J Minim Invasive Gynecol (Journal of minimally invasive gynecology)
[2018, 25(1):187-188]

Cited: 0 times

View full text PDF listing >>



Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.

Felicia T Roncolato, Florence Joly, Rachel O'Connell, Anne Lanceley, Felix Hilpert, Luke Buizen, Aikou Okamoto, Eriko Aotani, Sandro Pignata, Paul Donnellan, Amit Oza, Elisabeth Avall-Lundqvist, Jonathan S Berek, Florian Heitz, Amanda Feeney, Dominique Berton-Rigaud, Martin R Stockler, Madeleine King, Michael Friedlander, ,

<h4>Background</h4>Clinicians and patients often overestimate the benefits of chemotherapy, and overall survival (OS), in platinum resistant/refractory ovarian cancer (PRROC). This study sought to determine aspects of health-related quality of life and clinicopathological characteristics before starting chemotherapy that were associated with stopping chemotherapy early, shortened survival, and death within 30 days ... Read more >>

Oncologist (The oncologist)
[2017, 22(9):1117-1124]

Cited: 2 times

View full text PDF listing >>



Salpingo-Oophorectomy at the Time of Benign Hysterectomy: A Systematic Review.

William H Parker, Michael S Broder, Jonathan S Berek, JoAnn E Manson,

Obstet Gynecol (Obstetrics and gynecology)
[2017, 129(1):202]

Cited: 2 times

View full text PDF listing >>



Advertisement


Disclaimer

1.3351 s